SAN DIEGO, January 14, 2022 – The 40th Annual J.P. Morgan (JPM) Healthcare Conference was held online in the United States from January 10th to 13th. This premier conference is the largest and most informative health care investment symposium in the industry. It brings together thousands of global pharmaceutical companies, medical device companies, health service providers and investors to share the latest cutting-edge trend and the future of the industry. Dr. Kent Payne, CEO of BioDuro-Sundia, was invited to share the CRDMO service module with industry colleagues and investors. He gave an in-depth introduction on our comprehensive “one-stop shop” platform covering early-stage drug discovery to drug development to manufacturing phases, and our rapid development layout.

In 2022, while expanding the Drug Discovery division and CMC Drug Development division, BioDuro-Sundia acquired two commercialized drug manufacturing sites in the United States. The acquisition further enhanced our CRDMO business module, extended the layout of the production chain, and truly accomplished the "one-stop shop" service platform from drug research to development and to manufacturing. So far, BioDuro-Sundia has covered all the key phases in the drug development, including drug molecular design, screening, optimization, synthesis, biological pharmacology, oncology, biologics and pharmacokinetics, molecular diagnostic services，process R&D and scale-up production of intermediates , starting materials and API, analysis method development and testing, formulation R&D, GMP and non-GMP clinical production, commercialized production.

As the world's leading CRDMO, BioDuro-Sundia has built up 11 R&D sites around the world, with more than 2,500 professional employees. As of 2022, BioDuro-Sundia has participated in nearly 1,000 Class 1 new drug projects. More than 50 projects have been approved by US FDA/NMPA/TGA/EMA for clinical trial, of which 9 projects are approved by both China NMPA and the US FDA. We have built up partnership with more than 500 pharmaceutical companies over the world, including most of the TOP 20 leading pharma.

In the future, BioDuro-Sundia will continue to accelerate the global layout, improve technology competitiveness, enhance production capacity, strengthen our quality management system, and expand our talent pool to consolidate our market position, to better serve our partners with “one-stop shop” services and professional technical support, and to better benefit patients and the society.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO). We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 2,500 employees and 10 global sites across 7 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit www.bioduro-sundia.com